Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664637 · ClinicalTrials.gov registry record · Phase 2
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Phase 2 study, sponsored by Tranzyme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01664637: Clinical Trial Phase 2 study, sponsored by Tranzyme.
NCT01664637 is a Phase 2 study that was terminated before completion, run by Tranzyme. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01664637, a Phase 2 study, was terminated before completion, sponsored by Tranzyme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.
Interventions
- DRUG Placebo
- DRUG 10 mg TZP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Why NCT01664637 stopped before completion
NCT01664637 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01664637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01664637 about?
NCT01664637 is a clinical study titled "Diabetic Gastroparesis Efficacy/Safety Study of TZP-102". The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastrop...
What is the current status of trial NCT01664637?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2012-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01664637?
The interventions under investigation include: Placebo (DRUG), 10 mg TZP-102 (DRUG).
Who is sponsoring clinical trial NCT01664637?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01664637's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia